Circulating Tumor Antigen-specific Regulatory T Cells in Patients with Metastatic Melanoma

Overview

Journal Proc Natl Acad Sci U S A

Specialty Science

Date 2007 Dec 21

PMID 18093940

Citations 85

Authors

Luis Vence

A Karolina Palucka

Joseph W Fay

Tomoki Ito

Yong-Jun Liu

Jacques Banchereau

Hideki Ueno

Affiliations

Soon will be listed here.

Abstract

Although it is accepted that regulatory T cells (T regs) contribute to cancer progression, most studies in the field consider nonantigen-specific suppression. Here, we show the presence of tumor antigen-specific CD4(+) T regs in the blood of patients with metastatic melanoma. These CD4(+) T regs recognize a broad range of tumor antigens, including gp100 and TRP1 (melanoma tissue differentiation antigens), NY-ESO-1 (cancer/testis antigen) and survivin (inhibitor of apoptosis protein (IAP) family antigen). These tumor antigen-specific T regs proliferate in peripheral blood mononuclear cells (PBMC) cultures in response to specific 15-mer peptides, produce preferentially IL-10 and express high levels of FoxP3. They suppress autologous CD4(+)CD25(-) T cell responses in a cell contact-dependent manner and thus share properties of both naturally occurring regulatory T cells and type 1 regulatory T cells. Such tumor antigen-specific T regs were not detected in healthy individuals. These tumor antigen-specific T regs might thus represent another target for immunotherapy of metastatic melanoma.

Citing Articles

Tumor antigen‑specific interleukin‑10‑producing T‑cell response in patients with head and neck squamous cell carcinoma.

Horikawa M, Masuda K, Takahashi H, Tada H, Tomidokoro Y, Motegi M Oncol Lett. 2024; 28(4):456.

PMID: 39100998 PMC: 11294976. DOI: 10.3892/ol.2024.14589.

Role of Regulatory T Cells in Intracerebral Hemorrhage.

Shang Y, Zheng L, Du Y, Shang T, Liu X, Zou W Mol Neurobiol. 2024; 62(1):518-532.

PMID: 38877366 DOI: 10.1007/s12035-024-04281-7.

What do cancer-specific T cells 'see'?.

Shah S, Al-Omari A, Cook K, Paston S, Durrant L, Brentville V Discov Immunol. 2024; 2(1):kyac011.

PMID: 38567060 PMC: 10917189. DOI: 10.1093/discim/kyac011.

Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy.

Biri-Kovacs B, Banoczi Z, Tummalapally A, Szabo I Pharmaceutics. 2023; 15(2).

PMID: 36839774 PMC: 9963291. DOI: 10.3390/pharmaceutics15020452.

Identification of Age-Associated Transcriptomic Changes Linked to Immunotherapy Response in Primary Melanoma.

El-Helbawy N, El Zowalaty A Curr Issues Mol Biol. 2022; 44(9):4118-4131.

PMID: 36135194 PMC: 9497511. DOI: 10.3390/cimb44090282.

References

Fontenot J, Gavin M, Rudensky A . Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003; 4(4):330-6. DOI: 10.1038/ni904. View

Javia L, Rosenberg S . CD4+CD25+ suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother. 2003; 26(1):85-93. PMC: 2410039. DOI: 10.1097/00002371-200301000-00009. View

FUKAURA H, Kent S, Pietrusewicz M, Khoury S, Weiner H, Hafler D . Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest. 1996; 98(1):70-7. PMC: 507402. DOI: 10.1172/JCI118779. View

Allan S, Crome S, Crellin N, Passerini L, Steiner T, Bacchetta R . Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol. 2007; 19(4):345-54. DOI: 10.1093/intimm/dxm014. View

Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M . Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol. 1995; 155(3):1151-64. View

Kruger-Krasagakes S, Krasagakis K, Garbe C, Schmitt E, Huls C, Blankenstein T . Expression of interleukin 10 in human melanoma. Br J Cancer. 1994; 70(6):1182-5. PMC: 2033698. DOI: 10.1038/bjc.1994.469. View

Palucka A, Ueno H, Connolly J, Kerneis-Norvell F, Blanck J, Johnston D . Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother. 2006; 29(5):545-57. DOI: 10.1097/01.cji.0000211309.90621.8b. View

Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki N . Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A. 2003; 100(15):8862-7. PMC: 166404. DOI: 10.1073/pnas.1133324100. View

Bettelli E, Carrier Y, Gao W, Korn T, Strom T, Oukka M . Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature. 2006; 441(7090):235-8. DOI: 10.1038/nature04753. View

10.

Neumann F, Wagner C, Kubuschok B, Stevanovic S, Rammensee H, Pfreundschuh M . Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol Immunother. 2004; 53(7):589-99. PMC: 11034308. DOI: 10.1007/s00262-003-0492-6. View

11.

Kretschmer K, Apostolou I, Hawiger D, Khazaie K, Nussenzweig M, von Boehmer H . Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol. 2005; 6(12):1219-27. DOI: 10.1038/ni1265. View

12.

Davis I, Chen W, Jackson H, Parente P, Shackleton M, Hopkins W . Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A. 2004; 101(29):10697-702. PMC: 489997. DOI: 10.1073/pnas.0403572101. View

13.

Samy E, Parker L, Sharp C, Tung K . Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node. J Exp Med. 2005; 202(6):771-81. PMC: 2212949. DOI: 10.1084/jem.20041033. View

14.

Mucida D, Kutchukhidze N, Erazo A, Russo M, Lafaille J, Curotto de Lafaille M . Oral tolerance in the absence of naturally occurring Tregs. J Clin Invest. 2005; 115(7):1923-33. PMC: 1142115. DOI: 10.1172/JCI24487. View

15.

Shimizu J, Yamazaki S, Sakaguchi S . Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol. 1999; 163(10):5211-8. View

16.

Thornton A, Shevach E . CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med. 1998; 188(2):287-96. PMC: 2212461. DOI: 10.1084/jem.188.2.287. View

17.

Tarbell K, Yamazaki S, Olson K, Toy P, Steinman R . CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J Exp Med. 2004; 199(11):1467-77. PMC: 2211787. DOI: 10.1084/jem.20040180. View

18.

Tang Q, Adams J, Tooley A, Bi M, Fife B, Serra P . Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat Immunol. 2005; 7(1):83-92. PMC: 3057888. DOI: 10.1038/ni1289. View

19.

Woo E, Chu C, Goletz T, Schlienger K, Yeh H, Coukos G . Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 2001; 61(12):4766-72. View

20.

Gavin M, Torgerson T, Houston E, deRoos P, Ho W, Stray-Pedersen A . Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A. 2006; 103(17):6659-64. PMC: 1458937. DOI: 10.1073/pnas.0509484103. View